BAC signs license agreement with Hematech
BAC BV announced that it has entered into a license and supply agreement with Hematech, Inc., a subsidiary of Kirin Pharma that specialises in the production of human antibodies in transgenic cows. The license covers the use of a custom designed bovine IgG scavenging ligand which BAC had previously developed for Hematech. GE Healthcare will immobilize the BAC ligand on chromatographic media, which Hematech will use in the production of polyclonal human IgG from its transgenic cow platform.
"We have previously worked with Hematech to discover and develop the bovine IgG scavenging ligand and we are very pleased to continue this collaboration into a supply phase," said Laurens Sierkstra, CEO of BAC. "The success of this project further demonstrates the suitability of our ligands for a wide variety of applications and our ability to work in close partnership with collaborators to deliver ligands that exactly meet requirements."
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents

Signaling Pathway Suppresses Brain Tumors

Stardust in the bathroom - Nanoceramics: novel treatment for skin diseases

SeaBeLife awarded over €1.5 million in i-Nov innovation competition - Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD
Tobacco plants yield the first vaccine for the dreaded 'cruise ship virus'

Bacterial protein could help find materials for your next smartphone
